TREE NEWS update: China’s newly released national medical insurance drug catalog includes 51 Class 1 innovative drugs, the highest number on record, covering oncology, rare disease and chronic disease treatments with new mechanisms. The listing reflects faster drug development and steadier reimbursement coverage, accelerating the path of Chinese innovative drugs from laboratory to clinical use.
China’s 2025 State Drug List Adds 51 Innovative Drugs, a Record
The record count of Class 1 innovative drugs entering the national catalog signals that China's reimbursement pipeline is keeping pace with a faster domestic development cycle, which matters most for developers whose commercial case depends on catalog inclusion rather than out-of-pocket pricing. The emphasis on oncology, rare disease and chronic disease mechanisms points to where coverage is widening. Whether this pace of inclusion holds in future catalog cycles, and how the covered mechanisms translate into actual clinical uptake, is the open question worth tracking.
Generated by AI for reference only.
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.